Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-74.56M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -56.90% |
| Return on Assets (Trailing 12 Months) | -53.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 37.81M |
| Free Float | 35.01M |
| Market Capitalization | $59.74M |
| Average Volume (Last 20 Days) | 4.58M |
| Beta (Past 60 Months) | -1.64 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.34% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |